'The more overhype, the harder you fall': Schrödinger CEO warns on AI craze

Andrew Dunn

Senior Biopharma Correspondent

When sell-side analyst Evan Seigerman was preparing to start covering the startup Schrödinger this spring, he rang up the $3.5 billion biotech’s chief financial officer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

'The more overhype, the harder you fall': Schrödinger CEO warns on AI craze

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration reveals 'most favored nation' drug price country targets

In his first major policy rollout, Vinay Prasad looks to challenge existing 'dogma' on Covid vaccines

Updated: FDA adcomm splits votes on Genentech and J&J cancer drugs

RFK Jr. spars with senators over research cuts, HHS budget plan

Makary, Prasad spell out FDA ground rules for future Covid vaccine approvals

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

'The more over­hype, the hard­er you fal­l': Schrödinger CEO warns on AI craze

Senior Biopharma Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

'The more overhype, the harder you fall': Schrödinger CEO warns on AI craze